FibroGen Announces New Appointments to its Board of Directors
August 06 2020 - 4:01PM
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Dr.
Aoife Brennan and Dr. Ben Cravatt to its Board of Directors
effective August 5, 2020. Dr. Brennan is President and CEO of
Synlogic Inc. (Nasdaq:SYBX), a clinical stage biotechnology company
bringing the transformative potential of synthetic biology to
medicine. She joined Synlogic as Chief Medical Officer in 2016 and
was promoted to CEO in October 2018. Dr. Cravatt is a Professor and
the Norton B. Gilula Chair of Chemical Biology in the Department of
Chemistry at The Scripps Research Institute. His research group is
interested in developing chemical proteomic technologies that
enable protein and drug discovery on a global scale and applying
these methods to characterize biochemical pathways that play
important roles in human physiology and disease. Professor Cravatt
joined the faculty at The Scripps Research Institute in 1997.
“We are honored to welcome both Aoife and Ben to our Board of
Directors at this exciting point in FibroGen’s history. Aoife’s
deep experience in rare diseases and clinical development, and
Ben’s world-class expertise in biology and chemistry will provide
invaluable perspective to our Board.” said Enrique Conterno, Chief
Executive Officer, FibroGen.
- “I very much look forward to working with Mr. Conterno and the
other Directors to deliver on the unlimited potential of FibroGen
and its exciting portfolio of innovative medicines to address major
unmet needs in human health and disease.” said Dr. Cravatt.
- “I am excited to join FibroGen's Board as the company moves to
accelerate pivotal study development of pamrevlumab in multiple
orphan indications, and toward approval and launch of roxadustat
for the treatment of anemia associated with CKD worldwide, as well
as expanding into additional indications for the treatment of
anemia,” Dr. Brennan added. “I look forward to working with Enrique
and the entire Board of Directors to advance these important
products.”
Prior to joining Synlogic, Dr. Brennan served as Vice President
and Head of the Rare Disease Innovation Unit at Biogen where her
responsibilities included the global marketing approvals of
ALPROLIX™, ELOCTATE™ and SPINRAZA™ as well as the advancement of
several early-phase programs and external collaborations. She
served as a Director of Ra Pharmaceuticals from Sept 2018 through
its acquisition in April 2020. Dr. Brennan holds a medical degree
from Trinity College Dublin, Ireland and completed residency and
fellowship training in general internal medicine and endocrinology.
She has completed post-doctoral training in clinical research and
metabolism at the Beth Israel Deaconess Medical Center in Boston
and is a graduate of the Harvard Medical School Scholars in
Clinical Science Program.
A Professor at Scripps Research for more than twenty years, Dr.
Cravatt is an Associate Editor for Journal of the American Chemical
Society and is a co-founder of Activx Biosciences, Abide
Therapeutics, and Vividion Therapeutics. He serves on the Board of
Directors of Vividion, Boundless Bio, and Autobahn Therapeutics.
Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly
Award in Biological Chemistry, a Cope Scholar Award, the ASBMB
Merck Award, the RSC Jeremy Knowles Award, the AACR Award for
Achievement in Chemistry in Cancer Research, and memberships in the
American Academy of Arts and Sciences, National Academy of
Inventors, National Academy of Medicine, and National Academy of
Sciences. Dr. Cravatt obtained his undergraduate education at
Stanford University, receiving a B.S. in the Biological Sciences
and a B.A. in History. He then received a Ph.D. from The Scripps
Research Institute in 1996.
“I am delighted to welcome Drs. Brennan and Cravatt to the
FibroGen Board of Directors,” said Jim Schoeneck, chairman of the
FibroGen’s Board. “Both will bring fresh perspectives that will
help the Board and management advance our clinical development and
research agendas to bring potential first-in-class medicines to
patients suffering from chronic or life-threatening
conditions.”
About FibroGenFibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines to treat unmet needs. The Company is
currently developing and commercializing roxadustat, an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, for anemia
associated with chronic kidney disease (CKD). Roxadustat is also in
clinical development for anemia associated with myelodysplastic
syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab,
an anti-CTGF human monoclonal antibody, is in clinical development
for the treatment of idiopathic pulmonary fibrosis (IPF), locally
advanced unresectable pancreatic cancer, Duchenne muscular
dystrophy (DMD), and coronavirus (COVID-19). For more information,
please visit www.fibrogen.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding our strategy, future plans and
prospects, including statements regarding the development and
commercialization of the company’s product candidates. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and
potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2019 and our Quarterly Report on Form 10-Q for
quarter ended June 30, 2020 filed with the Securities and Exchange
Commission (SEC), including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contact:FibroGen, Inc.
Media Inquiries:Sara
Iacovino1.703.474.4452sara.iacovino@gcihealth.com
Investors:Michael Tung, M.D.Corporate Strategy / Investor
Relations 1.415.978.1434mtung@fibrogen.com
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Sep 2023 to Sep 2024